Is Prostaglandin E₂ Involved in the Pathogenesis of Fever? Effects of Interleukin-1 on the Release of Prostaglandins

HARRY A. BERNHEIM, Ph.D.

Department of Biology, Tufts University, Medford, Massachusetts

Received August 26, 1985

Interleukin-1 (IL-1) induces the formation of PGE₂ from monocytes, fibroblasts, muscle cells, and brain tissue by increasing the intracellular concentrations of Ca²⁺; this cation, in turn, activates a phospholipase which cleaves arachidonic acid from either diacylglycerol or a membrane phospholipid. In addition, IL-1 increases the synthesis of cyclooxygenase, as evidenced by the increased conversion of arachidonic acid into prostaglandins after fibroblasts are pre-incubated with IL-1. Evidence is also presented that fever is caused by interleukin-1-induced prostaglandin E₂.

INTRODUCTION

This paper will describe the effects of interleukin-1 (IL-1) on inducing prostaglandin E₂ (PGE₂). In addition, background information on the biochemistry and synthesis of prostaglandins will be presented.

BIOCHEMISTRY OF PGE₂

Prostaglandins are synthesized from arachidonic acid (AA) a 20-carbon fatty acid esterified to many cell phospholipids such as phosphotidylinositol [1]. AA is cleaved by a phospholipase—an enzyme which can be activated by a variety of stimuli such as Ca [2] or hormones [3]. Once released, AA is oxygenated by cyclooxygenase to yield the endoperoxide PGH₂. This compound is then converted to PGH₂ by the substitution of H for OH on carbon number 15. PGH₂ then acts as a substrate for various enzymes, one of which, PGE₂ isomerase, converts PGH₂ into PGE₂, an eicosanoid (i.e., a fatty acid with 20 carbons) which has 1 trans and 1 cis double bond and a five-member ring (carbon 8–12) containing an OH and a carbonyl group [1]. A second OH group is joined to carbon number 15 on the side chain [2] (Fig. 1).

PGE₂ synthesis can be blocked either by steroids (for example, glucocorticoids) or non-steroidal anti-inflammatory drugs (NSAID; e.g., aspirin). Steroids decrease the release of AA from phospholipids, perhaps by interfering with the activity of phospholipase [4,5]. NSAIDs, on the other hand, inhibit cyclooxygenase by interfering with two sites on the enzyme, one of which is a lipophilic region which has a high affinity for non-polar NSAIDs [1,6]. The ability of non-steroidals to inhibit PGE₂ production may explain why these compounds are, under many circumstances, good anti-pyretic agents [7].

EFFECTS OF IL-1 ON PGE₂ PRODUCTION BY VARIOUS CELL TYPES

IL-1 induces many different cell types to produce PGE₂; this phenomenon may represent a general characteristic of IL-1, although it must be stated that certain IL-1 mediated inflammatory effects (e.g., neutrophil degranulation) occur without PGE₂ [8].
**Monocytes**

When highly purified IL-1 is added to cell cultures of monocytes (1 x 10^6), PGE_2 levels rise within one hour from essentially 0 pg/ml of supernatant fluid to around 140 pg/ml. This response can be blocked by the addition of the NSAID ibuprofen to the incubation media [9]. The release of PGE_2 by monocytes may be important in immunoregulation, since PGE_2 suppresses the proliferation of certain thymus-derived lymphocytes (T cells) in response to antigens or mitogens [10]. Thus monocytic-derived IL-1 which aids the blastogenesis of mitogen- or antigen-stimulated T cells [11] also stimulates the release of PGE_2 from monocytes; the PGE_2, in turn, then limits T-cell proliferation (perhaps by altering intracellular levels of cyclic nucleotides [12]), a classic negative feedback system.

**Muscles**

During starvation, a decrease in plasma insulin levels permits the breakdown of muscle proteins to occur. The released amino acids are converted by the liver into glucose to meet the metabolic demands of the central nervous system [13,14]. In addition, acetyl groups and ketones derived from the breakdown of adipose tissue increase during starvation and act as the main source of fuel for the body (during prolonged starvation, the brain switches fuel from glucose to ketones [13]). The use of
ketones as a metabolic fuel allows the muscle tissues to be spared. On the other hand, during infection insulin levels are not suppressed and ketone levels do not rise [15,16,17]. As a result, metabolic demands, which may be higher than normal due to the presence of fever, are met mainly by glucose derived from skeletal muscle amino acids [18]. In addition, there is an increased utilization of amino acids by the liver to synthesize proteins associated with the inflammatory response—the so-called acute-phase inflammatory protein [7,19]. Thus, prolonged infections can cause significant muscle wasting, a common observation in patients with lymphomas and infectious diseases such as tuberculosis [20].

Interleukin-1 appears to be at least one of the molecules involved in muscle proteolysis during infections. Clowes et al. [21] have shown that the proteolytic activity of plasma from patients with trauma or sepsis is 190 percent of controls. The factor responsible for this activity is a peptide with a molecular weight of 4 kd and has been given the name proteolytic initiating factor (PIF). Baracos et al. in a series of experiments demonstrated that highly purified IL-1 increases the rate of proteolysis of rat muscle in vitro [22]. The proteolysis (measured by the rate of release of tyrosine into the supernatant media) was accompanied by increased levels of PGE$_2$; if indomethacin or other NSAIDs were added to the media with IL-1, PGE$_2$ release and the rate of proteolysis both decreased to control levels. In addition, rate of proteolysis and PGE$_2$ production in the presence of IL-1 both increased at higher (i.e., 39$^\circ$ vs. 36$^\circ$C) incubation temperatures. Since IL-1 breaks down in vivo into smaller molecular weight molecules (i.e., 4 kd) which retain biologic activity [23], it is quite possible that IL-1 and PIF are at least parts of the same molecule. In fact, trypsin digestion of 15 kd human IL-1 produces a 4 kd product which has almost all of the proteolytic activity of IL-1 and PIF [21,22,24]. Thus it appears that IL-1 is a catabolic molecule which mediates proteolysis via PGE$_2$.

**Fibroblasts**

The development of inflammatory lesions seen in rheumatoid arthritis may be due, at least in part, to IL-1, since IL-1 has been identified in effusions from joints of patients with rheumatoid arthritis [25,26]. In addition, monocyte-like cells from synovial explants synthesize IL-1 in response to soluble products [27] released by resident lymphocytes and to immune complexes [28]. Once released, IL-1 induces the synthesis of PGE$_2$ [29] and collagenase from synovial stellate cells (i.e., fibroblast-like cells found in rheumatoid arthritic lesions [30]). PGE$_2$ leads to an increase in the synthesis of osteoclast activating factor from lymphocytes [31], while collagenase destroys the matrix of the joint capsule and generates chemotactic factors for monocytes [32,33] and peripheral fibroblasts [34]. Moreover, degranulation products of collagenase stimulate the release of IL-1 from macrophages, resulting in a marked increase in PGE$_2$ and collagenase levels [35].

Additional experiments with human dermal fibroblasts have shown that IL-1 stimulates the release of PGE$_2$ from these cells as well. The dermal fibroblasts start to release PGE$_2$ four to six hours after stimulation and continue to do so for at least 48 hours. Inhibitors of cyclooxygenase (i.e., ibuprofen) eliminate the production of PGE$_2$ by fibroblasts in response to IL-1; in addition, inhibitors of mRNA translation (e.g., anisomycin) decrease the stimulatory effects of IL-1, indicating that IL-1 induces PGE$_2$ production by first stimulating the synthesis of new protein [36].
Neuronal Tissue

The ability of IL-1 to initiate fevers appears to be a result of its effect on the CNS rather than the periphery. More specifically, the action of IL-1 seems to be located primarily in the pre-optic anterior hypothalamus (PO/AH) in that microinjections of IL-1 into this area result in fever, while similar injections made into contiguous hypothalamic tissue have little or no effect on body temperature [37,18]). Furthermore, intravenous injection of IL-1 brings about a change in the discharge rate of thermosensitive neurons; such responses have been consistent with mechanisms of heat-conservation and production of fever [39].

IL-1 appears to bring about a fever by first inducing the production of PGE$_2$. Briefly, PGE$_2$ microinjected into the PO/AH produces fever in conscious animals almost indistinguishable from that produced by intravenously injected IL-1 [40]. In addition, endotoxin or IL-1 injected intravenously leads to increased levels of PGE$_2$ in the third ventricle or cisterna magna [41,42]. Hence a basic working hypothesis is that IL-1 induces PGE$_2$ synthesis in certain cells (neuronal or non-neuronal—see below) of the PO/AH. This concept is strengthened by the well-documented suppression of IL-1 induced fevers by antipyretics that inhibit the synthesis of PGE$_2$ from arachidonic acid [43]. Furthermore, PGE$_2$ synthesis inhibitors have no effect on normal body temperatures. It has been assumed that IL-1 gains access to specific receptors in the PO/AH, where new PGE$_2$ is synthesized with the concomitant result of fever. However, studies using intrinsically injected $^{125}$I-labeled IL-1 have failed to show concentrations of the pyrogen in the anterior hypothalamus [44]. Thus the receptive cells for IL-1 may lie outside the blood-brain barrier (i.e., the organum vasculosum lamina terminalis [45]).

Brain minces stimulated \textit{in vitro} with purified IL-1 release PGE$_2$ within 30–60 minutes after stimulation [46]. Tissue from both the temporal cortex and anterior hypothalamus release similar amounts of PGE$_2$ in response to IL-1, indicating that receptors for IL-1 are widespread. The NSAID ibuprofen, which reduces fever in humans and is 20 times more potent than acetylsalicylic acid [47], markedly reduced the amount of PGE$_2$ released by brain minces incubated with IL-1.

Ziel and Krupp, using brain homogenates, showed that IL-1 increases the cerebral prostaglandin synthetase system [48]. In addition, Fagan and Goldberg [49] have shown that brain slices from rats which had been injected with endotoxin (an agent which induces the release of IL-1 \textit{in vivo} and \textit{in vitro}) and which subsequently became febrile released significantly more PGE$_2$ than brain slices from saline-injected animals. In none of these experiments, however, are the cells which release PGE$_2$ in response to IL-1 identified. However, Fontana et al. have demonstrated that cultured murine astrocytes (macrophage-like cells which, however, are non-phagocytic and lack Fc and C$_3$ receptors) release both IL-1 and PGE$_2$ in response to endotoxin [50]. Thus it may be that astrocytes or other non-neuronal cells in the brain (i.e., dendritic cells) produce PGE$_2$ in response to IL-1 during the pathogenesis of fever (Table 1).

\textbf{MODE OF ACTION OF IL-1 IN INDUCING SYNTHESIS OF PGE$_2$}

There is substantial evidence [51] that many agonists exert their effects by influencing the metabolism of phosphoinositides (compounds containing a molecule of glycerol with two esterified fatty acids and one molecule of inositol with one or more phosphate groups). For example, vasopressin causes a rapid breakdown of phosphoti-
dylinositol 4,5 bisphosphate into diacylglycerol (DAG) and inositol triphosphate [52]. Inositol acts as a second messenger by increasing the levels of intracellular Ca (coming from either internal or external sources [53]), while DAG activates C-kinase, an enzyme which phosphorylates specific regulating enzymes [54,55]. Most of the DAG produced by receptor agonist interactions has arachidonic acid (AA) in its 2 position [56]. Once DAG is formed, AA can be cleaved from the parent molecule by either diacylglycerol lipase [57,58] or by a phosphatidic acid-specific phospholipase after conversion of DAG into phosphatidic acid [59]. The AA, in turn, is converted into prostaglandin by the cyclooxygenase enzyme pathway. The DAG enzymatic pathways require increased intracellular levels of Ca++ to operate. There is, however, an alternate route by which AA can be generated. In this system a non-specific, Ca-dependent phospholipase, which has a higher requirement of Ca to operate than the enzymes in the DAG pathway, cleaves AA from various cell membrane phospholipids [60]. 

Since the enzymes responsible for the cleaving of AA require Ca to be active, it may be that IL-1 exerts its effects, in part, by causing an increase in intracellular levels of Ca. Various experiments have shown that this is indeed the case. For example, calcium ionophores (e.g., A23187) can substitute for IL-1 in inducing PGE2 production and proteolysis in rat muscle strips [61].

If Ca is removed from the media, A23187 induces significantly less PGE2 production and muscle proteolysis. In addition, if mepacrine, an inhibitor of Ca-dependent phospholipase, is added to the incubation media, PGE2 and proteolysis are both decreased in response to A23187. This result indicates that Ca influx induces the synthesis of prostaglandin by first activating a phospholipase.

Besides activating Ca-dependent phospholipases, IL-1 may also increase the activity of cyclooxygenase. Human dermal fibroblasts when pre-incubated with IL-1 converted significantly more AA into prostaglandin when compared to control cells [62]. In addition, microsomal cyclooxygenase activity increases after cells are pre-incubated with IL-1 for 48 hours. If the fibroblasts are pre-incubated in the presence of both IL-1 and protein synthesis inhibitors, there is no increase in AA conversion. Thus, it appears that IL-1 increases the activity of cyclooxygenase by increasing the enzyme's rate of synthesis.

CONCLUSIONS

It seems likely that IL-1 causes fever by first inducing the synthesis of PGE2. Evidence for this is that injection of PGE2 into the brain produces a brisk monophasic fever, as does IL-1. Moreover, intravenous injection of IL-1 leads to increases in cerebrospinal fluid PGE2 which can be correlated with fever height. In addition, NSAIDs eliminate or at least attenuate IL-1 induced fevers but not fevers caused by
injection of PGE₂. Finally, IL-1 stimulates the production of PGE₂ from many cells and tissues studied in vitro, including cells located in the brain.

IL-1 may initiate PGE₂ synthesis by increasing internal concentration of Ca, a cation which can activate a phospholipase(s) that cleaves AA from phospholipids or DAG. In addition, IL-1 increases the synthesis of cyclooxygenase as evidenced by the increased conversion of AA into PGE₂ by fibroblasts preincubated with IL-1. This increased conversion is blocked if the fibroblasts are incubated with both IL-1 and a protein synthesis inhibitor, indicating that IL-1 induces the increased synthesis of cyclooxygenase.

The exact role of PGE₂ in fever awaits further experimental evidence. However, with the recent availability of recombinant IL-1 [63], cells responsive to IL-1 in the brain will be able to be identified, as well as their ability to synthesize PGE₂ after IL-1 stimulation.

REFERENCES

1. Kuehl FA, Egan RW: Prostaglandins, arachidonic acid, and inflammation. Science 210:978–984, 1980
2. Lapetina EG, Cuatrecasas P: Rapid inactivation of cyclooxygenase activity after stimulation of intact platelets. Proc Natl Acad Sci USA 76:121–125, 1979
3. Hong SL, Levine I: Stimulation of prostaglandin synthesis by bradykinin and thrombin and their mechanisms of action on MCS-5 fibroblasts. J Biol Chem 251:5814–5816, 1976
4. Gryglewski RJ, Panezenko B, Korbut R, Grodzinska L, Ocketkiewica A: Corticosteroids inhibit prostaglandin release from perfused mesenteric blood vessels of rabbit and from perfused lungs of sensitized guinea pigs. Prost 10:343–355, 1975
5. Flower RJ, Blackwell GT: Anti-inflammatory steroids induce biosynthesis of a phospholipase A₂ inhibitor which prevents prostaglandin generation. Nature 278:456–459, 1979
6. Smith WL, Lands WEM: Oxygenation of polyunsaturated fatty acids during prostaglandin biosynthesis by sheep vesicular gland. Biochem 11:3276–3285, 1972
7. Dinarello CA: Interleukin-1. Rev Inf Dis 6:51–95, 1984
8. Klempner MS, Dinarello CA, Gallin JI: Human leukocyte pyrogen induces release of specific granule contents from human neutrophils. J Clin Invest 61:1330–1336, 1978
9. Dinarello CA, Marnoy SO, Rosenwasser LJ: Role of arachidonate metabolism in the immunoregulatory function of human leukocyte pyrogen/lymphocyte activating factor/interleukin-1. J Immunol 130:890–895, 1983
10. Ellner JJ: Suppressor cells of man. Clin Immunol Rev 1:119–214, 1981
11. Rosenwasser LJ, Dinarello CA: Ability of human leukocytic pyrogen to enhance phthogemaggglutinin induced murine thymocyte proliferation. Cell Immunol 63:134–142, 1981
12. Goodwin J, Bankhurst A, Messner R: Suppression of human T-cell mitogenesis by prostaglandin. Existence of a prostaglandin producing suppressor cell. J Exp Med 146:1719–1734, 1977
13. Ruderman NB: Muscle amino acid metabolism and glyconeogenesis. Ann Rev Med 26:245–258, 1975
14. Goldberg AL, Chong TW: Regulation and significance of amino acid metabolism in skeletal muscle. Fed Proc 37:2301–2307, 1979
15. Neufeld HA, Pace JA, White FE: The effects of bacterial infections on ketone concentrations in rat liver and blood on free fatty acid concentrations in rat blood. Metab 25:877–884, 1976
16. Keenan PA, Moldawer LL, Yang RD, Kawamura I, Blackburn GL, Bistrian BR: An altered response by peripheral leukocytes to synthesis or release of leukocyte endogenous mediator in critically ill, protein malnourished patients. J Lab Clin Med 100:844–857, 1982
17. Neufeld HA, Pace JG, Kaminski MV, Gearse DT, Jahrlin PB, Wannemacher RW, Beisel WR: A probably endocrine basis for the depression of ketone bodies during infections or inflammatory states in rats. Endo 107:596–601, 1980
18. Wilmore DW: Energy production, metabolism of fat and glucose. In Relevance of Nutrition to Sepsis. Edited by J Fischer, JW Alexander. Columbus, OH, Ross Laboratories, 1982, pp 51–61
19. Sztein MB, Vogel SN, Sipe JD: The role of macrophages in the acute-phase response SAA inducer is closely related to lymphocyte activating factor and endogenous pyrogen. Cell Imm 63:164–176, 1981
20. Beisel WR: Metabolism response to infection. Ann Rev Med 26:9–20, 1975
21. Clowes GHA Jr, Georse BC, Villée CA, Saravis CA: Muscle proteolysis induced by a circulating peptide in patients with sepsis or trauma. New Eng J Med 308:545–552, 1983
22. Baracos V, Rodemann P, Dinarello CA, Goldberg AL: Stimulation of muscle protein degradation and prostaglandin E2 release by leukocytic pyrogen (interleukin-1). A mechanism for the increased degradation of muscle proteins during fever. New Eng J Med 308:553–558, 1983
23. Cannon JG, Dinarello CA: Increased plasma interleukin-1 activity in women after ovulation. Science 227:1247–1249, 1985
24. Dinarello CA, Clowes GHA Jr, Gordon AH, Saravis CA, Wolff SM: Cleavage of human interleukin-1: Isolation of a peptide fragment from plasma of febrile humans and activated monocytes. J Immunol 133:1332–1338, 1984
25. Fontana AH, Hengartner H, Weber E, Fehr K, Grab PJ, Cohen G: Interleukin-1 activity in the synovial fluid of patients with rheumatoid arthritis. Arth Rheum 2:49–53, 1982
26. Wood DD, Hrie EL, Dinarello CA, Coehn PL: Isolation of an interleukin-1-like factor from human joint effusions. Arth Rheum 26:975–983, 1983
27. Dayer JM, Robinson DR, Krane SM: Prostaglandin production by rheumatoid synovial cells. Stimulation by a factor from human mononuclear cells. J Exp Med 145:1399–1404, 1977
28. Huybrechts-Godin G, Hauser P, Vases G: Macrophage-fibroblast interactions in collagenase production and cartilage degradation. Biochem J 184:643–650, 1979
29. Robinson DR, McGuire M, Bastian D, Kantonial F, Levine L: Effects of anti-inflammatory drugs on prostaglandin production by rheumatoid synovial tissue. Prost Med 1:461–477, 1978
30. Mizel SB, Dayer JM, Krane SM, Mergenhagen SE: Stimulation of rheumatoid synovial cell collagenase and prostaglandin production by partially purified lymphocyte-activating factor (interleukin-1). Proc Natl Acad Sci USA 78:2474–2477, 1981
31. Yoneda T, Mundy GR: Prostaglandins are necessary for osteoclast-activating factor production by activated peripheral blood leukocytes. J Exp Med 149:279–283, 1979
32. Postlethwaite AE, Kang AH: Collagen and collagen-peptide induced chemotaxis of human blood monocytes. J Exp Med 143:1299–1307, 1976
33. Stuart JM, Postlethwaite AE, Townes AS, Kang AH: Cell-mediated immunity to collagen and collagen alpha chains in rheumatoid arthritis and other rheumatic diseases. Am J Med 64:13–18, 1980
34. Postlethwaite AE, Seyer JM, Kang AH: Chemotactic attraction of human fibroblasts to type I, II and III collagens and collagen-derived peptides. Proc Natl Acad Sci USA 75:871–875, 1978
35. Dayer JM, Trentham DE, Krane SM: Collagens act as ligands to stimulate human monocytes to produce mononuclear cell factor (MCF) and prostaglandins (PGE2). Collagen Rel Res 2:523–540, 1980
36. Bernheim HA, Dinarello CA: Effects of purified human interleukin-1 on the release of prostaglandin E2 from fibroblasts. Br J Rheum, in press
37. Rosendorff C, Mooney JJ: Central nervous system sites of action of purified leucocyte pyrogen. Am J Physiol 220:597–603, 1971
38. Lipton JM, Kennedy JI: Central thermosensitivity during fever produced by intra PO/AH and intravenous injection of pyrogen. Brain Res Bull 4:23–24, 1979
39. Schoener EP, Wang SC: Leukocytic pyrogen and sodium acetyl salicylate on hypothalamic neurons in the cat. Am J Physiol 229:185–190, 1975
40. Stitt JT: Prostaglandin E2 fever induced in rabbits. J Physiol 232:163–179, 1973
41. Feldberg WA, Gupta KP: Pyrogen fever and prostaglandin-like activity in cerebrospinal fluid. J Physiol 228:41–53, 1973
42. Bernheim HA, Gilbert TM, Stitt JT: Prostaglandin E levels in third ventricular cerebrospinal fluid of rabbits during fever and changes in body temperature. J Physiol 301:69–78, 1980
43. Vane JR: Inhibition of prostaglandin synthesis as a mechanism of action of aspirin-like drugs. Nature 231:232–235, 1971
44. Dinarello CA, Meiner P, Wolff SM: Radiolabeling and deposition in rabbits of purified human leukocytic pyrogen. Clin Res 26:522A, 1978
45. Stitt JT, Shimada SG, Bernheim HA: Microinjection of zymosan and lipopolysaccharide into the organum vasculosum laminae terminalis of rats enhances their febrile responsiveness to endogenous pyrogen. In Thermal Physiology. Edited by JRS Hales. New York, Raven Press, 1984, pp 553–558
46. Dinarello CA, Bernheim HA: Ability of human leukocytic pyrogen to stimulate brain prostaglandin synthesis in vitro. J Neurochem 37:702–708, 1981
47. Similia S, Kovvalainen K, Keinanen S: Oral antipyretic therapy. Scan J Rheum 5:81–83, 1976
48. Ziel R, Krupp P: Influence of endogenous pyrogen on the cerebral prostaglandin-synthetase system. Experientia 32:1451–1453, 1976
49. Fagan JM, Goldberg AL: Muscle protein breakdown, prostaglandin E₂ production, and fever upon bacterial infection. J Leuk Bio 37:702–703, 1985
50. Fontana A, Kristensen F, Dubs R, Gemsa D, Weber E: Production of prostaglandin E₂ and interleukin-1 like factors by cultured astrocytes and C₆ glioma cells. J Immunol 129:2413–2419, 1982
51. Berridge MJ: Inositol triphosphate and diacylglycerol as secondary messengers. Biochem J 220:345–360, 1984
52. Creba JA, Downes CP, Hawkins PT, Brewster G, Mitchell RH, Kirk CJ: Breakdown of phosphatidylinositol 4-phosphate and phosphatidylinositol 4,5 bisphosphate in rat hepatocytes stimulated by vasopressin and other Ca²⁺-mobilizing hormones. Biochem J 212:733–742, 1983
53. Takai U, Kishimato A, Kikkawa U, Mori T, Nishizuka Y: Unsaturated diacylglycerol as a possible messenger for the activation of calcium activated, phospholipid-dependent protein kinase system. Biophys Res Commun 91:1218–1224, 1979
54. Nishizuka Y: Phospholipid degradation and signal translation for protein phosphorylation. Trends Biochem Sci 8:13–16, 1983
55. Bell RL, Kennerly DA, Stanford N, Majerus PW: Diglyceride lipase: A pathway for arachidonate release from human platelets. Proc Natl Acad Sci USA 76:3238–3241, 1979
56. Prescott SM, Majerus PW: Characterization of 1,2-diacylglycerol hydrolysis in human platelets. Demonstration of an arachidonoyl-monoacylglycerol intermediate. J Biol Chem 258:764–769, 1983
57. Billah MM, Lapetina EG, Cuatrecasas P: Phospholipase A₂ activity specific for phosphatidic acid. J Biol Chem 256:5399–5403, 1981
58. Billah MM, Lapetina EG, Cuatrecasas P: Phospholipase A₂ and phospholipase C activities of platelets. Differential substrate specificity, Ca²⁺ requirement, pH dependence, and cellular localization. J Biol Chem 255:10227–10231, 1980
59. Rodemann HP, Waxman L, Goldberg AL: The stimulation of protein degradation in muscle by Ca²⁺ is mediated by prostaglandin E₂ and does not require the calcium-activated protease. J Biol Chem 257:8716–8723, 1982
60. Whiteley PJ, Needleman P: Mechanism of enhanced fibroblast arachidonic acid metabolism by mononuclear cell factor. J Clin Invest 74:2249–2253, 1984
61. Auron PE, Webb AC, Rosenwasser LJ, Mucci SF, Rich A, Wolff SM, Dinarello CA: Nucleotide sequence of human monocyte interleukin-1 precursor cDNA. Proc Natl Acad Sci USA 81:7907–7911, 1984